MedAdvisor Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de MedAdvisor de 69.1% y 13.4% por año respectivamente. Se prevé que el BPA crezca en un 69.2% al año. Se espera que la rentabilidad financiera sea de 18.1% en 3 años.

Información clave

69.1%

Tasa de crecimiento de los beneficios

69.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare Services	20.8%
Tasa de crecimiento de los ingresos	13.4%
Rentabilidad financiera futura	18.1%
Cobertura de analistas	Low
Última actualización	01 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Nov 09

Is MedAdvisor (ASX:MDR) A Risky Investment?

Oct 11

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Mar 08

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

Feb 10

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

Jan 18

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

Dec 22

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Dec 18

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

Nov 22

Previsiones de crecimiento de beneficios e ingresos

ASX:MDR - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2027	184	13	16	21	2
6/30/2026	162	9	14	16	3
6/30/2025	142	2	5	9	3
6/30/2024	122	1	3	5	N/A
3/31/2024	116	-4	-2	0	N/A
12/31/2023	109	-9	-7	-6	N/A
9/30/2023	104	-10	-4	-4	N/A
6/30/2023	98	-11	-2	-1	N/A
3/31/2023	96	-8	7	7	N/A
12/31/2022	93	-5	16	16	N/A
9/30/2022	80	-11	8	8	N/A
6/30/2022	68	-17	-1	0	N/A
3/31/2022	66	-16	-6	-5	N/A
12/31/2021	64	-14	-11	-11	N/A
9/30/2021	52	-14	-12	-12	N/A
6/30/2021	39	-14	-13	-13	N/A
3/31/2021	28	-13	-10	-9	N/A
12/31/2020	18	-12	-6	-6	N/A
9/30/2020	14	-11	-8	-7	N/A
6/30/2020	10	-10	-9	-9	N/A
3/31/2020	9	-9	-9	-8	N/A
12/31/2019	9	-9	-8	-8	N/A
9/30/2019	9	-8	-8	-7	N/A
6/30/2019	8	-8	-7	-7	N/A
3/31/2019	8	-7	-6	-6	N/A
12/31/2018	7	-7	-6	-5	N/A
9/30/2018	7	-6	-5	-4	N/A
6/30/2018	7	-4	-4	-3	N/A
3/31/2018	6	-4	N/A	-3	N/A
12/31/2017	6	-4	N/A	-3	N/A
9/30/2017	5	-4	N/A	-3	N/A
6/30/2017	4	-3	N/A	-2	N/A
3/31/2017	3	-4	N/A	-3	N/A
12/31/2016	2	-4	N/A	-3	N/A
9/30/2016	2	-4	N/A	-3	N/A
6/30/2016	1	-3	N/A	-3	N/A
3/31/2016	1	-2	N/A	-2	N/A
12/31/2015	2	-1	N/A	-1	N/A
9/30/2015	2	-1	N/A	-1	N/A
6/30/2015	2	-1	N/A	0	N/A
6/30/2014	1	-1	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (69.1% al año) de MDR es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (69.1% al año) de MDR crezcan más rápidamente que el mercado Australian (12.5% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de MDR crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (13.4% al año) de MDR crezcan más rápidamente que los del mercado Australian (5.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 13.4% al año) de MDR crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de MDR sea baja dentro de 3 años (18.1%).

MedAdvisor Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date pushed back to 2025

Price target increased by 13% to AU$0.51

Consensus EPS estimates upgraded to AU$0.0033 loss

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 11%, revenue upgraded

Forecast breakeven date pushed back to 2026

Recent updates

New minor risk - Share price stability

New minor risk - Market cap size

Lacklustre Performance Is Driving MedAdvisor Limited's (ASX:MDR) Low P/S

MedAdvisor Limited Announces the Resignation of Anthony Tassone as Non-Executive Director

MedAdvisor Limited, Annual General Meeting, Nov 14, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

MedAdvisor Limited Announces Board Resignations

Forecast breakeven date pushed back to 2025

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Price target increased by 13% to AU$0.51

Consensus EPS estimates upgraded to AU$0.0033 loss

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 11%, revenue upgraded

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Forecast breakeven date pushed back to 2026

New minor risk - Profitability

Now 24% overvalued after recent price rise

Consensus estimates of losses per share improve by 33%

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Non-Executive Director recently bought AU$1.2m worth of stock

MedAdvisor Limited, Annual General Meeting, Nov 28, 2023

Consensus estimates of losses per share improve by 32%

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 50%

MedAdvisor Limited Announces Board Changes

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Consensus EPS estimates fall by 80%, revenue upgraded

First half 2023 earnings released: EPS: AU$0.009 (vs AU$0.02 loss in 1H 2022)

Price target increased to AU$0.40

MedAdvisor Limited Provides Revenue Guidance for the First Half of the Fiscal Year 2023

MedAdvisor Limited Appoints Kevin Hutchinson as Director

Less than half of directors are independent

MedAdvisor Limited to Report Q1, 2023 Results on Oct 28, 2022

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited, Annual General Meeting, Nov 30, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

MedAdvisor Limited (ASX:MDR) entered a binding agreement to acquire GuildLink Pty Ltd from Guild Group Holdings Limited for AUD 8 million.

MedAdvisor Limited Announces Executive Changes

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

MedAdvisor Limited Announces Change of Managing Director

Price target decreased to AU$0.40

No longer forecast to breakeven

Less than half of directors are independent

MedAdvisor Limited Announces Retirement of Robert Read as CEO

Consensus forecasts updated

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited to Report First Half, 2022 Results on Feb 25, 2022

MedAdvisor Limited Appoints Raeann Grossman to the Board as A Non-Executive Director

Independent Non-Executive Director Peter Bennetto has left the company

Non-Executive Director recently sold AU$2.5m worth of stock

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Is MedAdvisor (ASX:MDR) A Risky Investment?

Less than half of directors are independent

Full year 2021 earnings released

Non-Executive Director has left the company

MedAdvisor Limited announced that it has received AUD 5.25 million in funding

New 90-day low: AU$0.34

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

First half 2021 earnings released: AU$0.029 loss per share (vs AU$0.024 loss in 1H 2020)

MedAdvisor Limited to Report First Half, 2021 Results on Feb 25, 2021

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

New 90-day low: AU$0.34

Non-Executive Chairman of the Board recently bought AU$70k worth of stock

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

MedAdvisor Limited Signs an Additional One-Year Deal with A Major Global Pharmaceutical Company

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

New 90-day low: AU$0.36